LT4714B - Vaistų įvedimo įtaisas ir farmacinė kompozicija, skirti gydyti sekinančius sindromus - Google Patents

Vaistų įvedimo įtaisas ir farmacinė kompozicija, skirti gydyti sekinančius sindromus Download PDF

Info

Publication number
LT4714B
LT4714B LT99-148A LT99148A LT4714B LT 4714 B LT4714 B LT 4714B LT 99148 A LT99148 A LT 99148A LT 4714 B LT4714 B LT 4714B
Authority
LT
Lithuania
Prior art keywords
dmf
therapeutic composition
alkyl groups
methyl
group
Prior art date
Application number
LT99-148A
Other languages
English (en)
Lithuanian (lt)
Other versions
LT99148A (lt
Inventor
Michelle Olga Patricia Giesteira Visser
Original Assignee
Cryopreservation Technologies Cc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/874,425 external-priority patent/US5935597A/en
Application filed by Cryopreservation Technologies Cc filed Critical Cryopreservation Technologies Cc
Publication of LT99148A publication Critical patent/LT99148A/xx
Publication of LT4714B publication Critical patent/LT4714B/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
LT99-148A 1997-06-13 1999-12-20 Vaistų įvedimo įtaisas ir farmacinė kompozicija, skirti gydyti sekinančius sindromus LT4714B (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/874,425 US5935597A (en) 1995-12-15 1997-06-13 Drug delivery devices and methods for treatment of viral and microbial infections and wasting syndromes

Publications (2)

Publication Number Publication Date
LT99148A LT99148A (lt) 2000-07-25
LT4714B true LT4714B (lt) 2000-10-25

Family

ID=25363728

Family Applications (1)

Application Number Title Priority Date Filing Date
LT99-148A LT4714B (lt) 1997-06-13 1999-12-20 Vaistų įvedimo įtaisas ir farmacinė kompozicija, skirti gydyti sekinančius sindromus

Country Status (34)

Country Link
EP (1) EP1011567A1 (is)
JP (1) JP4531141B2 (is)
KR (1) KR20010013709A (is)
CN (1) CN1260703A (is)
AP (1) AP1629A (is)
AR (1) AR012970A1 (is)
AU (1) AU7831598A (is)
BG (1) BG103997A (is)
BR (1) BR9810095A (is)
CA (1) CA2295176A1 (is)
CZ (1) CZ298510B6 (is)
EA (1) EA200000011A1 (is)
EE (1) EE9900562A (is)
ES (1) ES2161187B1 (is)
FI (1) FI19992648L (is)
GB (1) GB2341319B (is)
HU (1) HUP0003034A2 (is)
ID (1) ID23516A (is)
IL (2) IL133396A0 (is)
IS (1) IS5289A (is)
LT (1) LT4714B (is)
LV (1) LV12490B (is)
NO (1) NO996117L (is)
NZ (1) NZ501669A (is)
OA (1) OA11307A (is)
PL (1) PL196256B1 (is)
RO (1) RO121252B1 (is)
SI (1) SI20191A (is)
SK (1) SK172299A3 (is)
TN (1) TNSN98086A1 (is)
TR (1) TR200000540T2 (is)
WO (1) WO1998056325A1 (is)
YU (1) YU66099A (is)
ZA (1) ZA984649B (is)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005004729A1 (en) * 2003-06-30 2005-01-20 Alza Corporation Method for coating skin piercing microprojections
AP2006003648A0 (en) * 2003-12-05 2006-06-30 Namibia Medical Invest Pty Ltd Patch

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE60941B1 (en) * 1986-07-10 1994-09-07 Elan Transdermal Ltd Transdermal drug delivery device
US4855294A (en) * 1988-09-06 1989-08-08 Theratech, Inc. Method for reducing skin irritation associated with drug/penetration enhancer compositions
US5534260A (en) * 1989-02-23 1996-07-09 University Of Utah Percutaneous drug delivery system
US5028435A (en) * 1989-05-22 1991-07-02 Advanced Polymer Systems, Inc. System and method for transdermal drug delivery
US5624912A (en) * 1991-08-21 1997-04-29 Burcoglu; Arsinur Method of treating HIV infection and related secondary infections with defibrotide
NZ249032A (en) * 1992-02-20 1996-09-25 Merrell Dow Pharma Stilbene disulphonic acid derivatives substituted in the 4- and 4'-positions by thioureido, thiocarbonate ester, and thiocarbamate and thiocarbamoyloxy (and -omino) and thioamide groups; use in treating viral diseases
IL124733A0 (en) * 1995-12-15 1999-01-26 Cryopreservation Tech Cc Composition for organ cryopreservation and treatment of viral and bacterial infections

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
A. G. DALGLEISH ET AL.: "The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus", NATURE, 1984, pages 763 - 767, XP000919059, DOI: doi:10.1038/312763a0
BARRE-SINOUSSI ET AL.: "Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS)", SCIENCE, 1983, pages 868 - 870
CHOE, H. ET AL.: "The -chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates", CELL, 1996
DAVID KLATZMANN: "T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV", NATURE, 1984, pages 767 - 768
F. CLAVEL: "Isolation of a new human retrovirus from West African patients with AIDS", SCIENCE, 1986, pages 343 - 346, XP009021606, DOI: doi:10.1126/science.2425430
HAMMARSKJOLD ML ET AL.: "The molecular biology of the human immunodeficiency virus", BIOCHIMICA ET BIOPHYSICA ACTA, 1989, pages 269 - 280
J. P. MADON ET AL.: "The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain", CELL, 1986, pages 333 - 348
M. GUYADER: "Genome organization and transactivation of the human immunodeficiency virus type 2", NATURE, 1987, pages 662 - 669, XP000605289, DOI: doi:10.1038/326662a0
MIEDEMA F ET AL.: "Changing virus-host interactions in the course of HIV-1 infection", IMMUNOL REV., 1994, pages 35 - 72
R. C. GALLO ET AL.: "Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS", SCIENCE, 1984, pages 500 - 503
SATTENTAU QJ, MOORE JP.: "The role of CD4 in HIV binding and entry", PHILOS TRANS R SOC LOND B BIOL SCI., 1993, pages 59 - 66

Also Published As

Publication number Publication date
TR200000540T2 (tr) 2000-09-21
EA200000011A1 (ru) 2000-08-28
AR012970A1 (es) 2000-11-22
NO996117D0 (no) 1999-12-10
IL133396A0 (en) 2001-04-30
ID23516A (id) 2000-04-27
BR9810095A (pt) 2001-11-13
IL133396A (en) 2006-10-05
SI20191A (sl) 2000-10-31
AU7831598A (en) 1998-12-30
KR20010013709A (ko) 2001-02-26
LT99148A (lt) 2000-07-25
PL196256B1 (pl) 2007-12-31
EP1011567A4 (en) 2000-06-28
JP2002511862A (ja) 2002-04-16
CZ9904473A3 (cs) 2001-03-14
LV12490B (en) 2000-12-20
IS5289A (is) 1999-12-08
ZA984649B (en) 1999-12-17
WO1998056325A1 (en) 1998-12-17
FI19992648A7 (fi) 2000-02-03
YU66099A (sh) 2002-10-18
AP9901708A0 (en) 1999-12-31
EP1011567A1 (en) 2000-06-28
EE9900562A (et) 2000-06-15
ES2161187B1 (es) 2003-08-16
CA2295176A1 (en) 1998-12-17
BG103997A (bg) 2001-07-31
NZ501669A (en) 2001-09-28
GB2341319B (en) 2002-02-27
TNSN98086A1 (fr) 2005-03-15
GB2341319A (en) 2000-03-15
OA11307A (en) 2003-10-24
RO121252B1 (ro) 2007-02-28
JP4531141B2 (ja) 2010-08-25
PL338439A1 (en) 2000-11-06
GB9929189D0 (en) 2000-02-02
CN1260703A (zh) 2000-07-19
HUP0003034A2 (hu) 2000-12-28
NO996117L (no) 2000-02-11
SK172299A3 (en) 2000-09-12
ES2161187A1 (es) 2001-11-16
FI19992648L (fi) 2000-02-03
AP1629A (en) 2006-07-11
LV12490A (en) 2000-06-20
CZ298510B6 (cs) 2007-10-24

Similar Documents

Publication Publication Date Title
Bodenheimer Jr et al. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial
Luzuriaga et al. Pharmacokinetics, safety, and activity of nevirapine in human immunodeficiency virus type 1-infected children
Faulds et al. Didanosine: a review of its antiviral activity, pharmacokinetic properties and therapeutic potential in human immunodeficiency virus infection
Land et al. Decreased in vitro susceptibility to zidovudine of HIV isolates obtained from patients with AIDS
Hung et al. Pharmacokinetics of oral acyclovir (Zovirax) in the eye.
Lundgren et al. Antiviral effects of 3′-fluorothymidine and 3′-azidothymidine in cynomolgus monkeys infected with simian immunodeficiency virus
McCracken Jr et al. Cytosine arabinoside in the treatment of congenital cytomegalic inclusion disease
Cohen et al. Comparative clinical and laboratory evaluation of the prophylactic capacity of ribavirin, amantadine hydrochloride, and placebo in induced human influenza type A
Mathes et al. Pre-and postexposure chemoprophylaxis: evidence that 3'-azido-3'-dideoxythymidine inhibits feline leukemia virus disease by a drug-induced vaccine response
US5935597A (en) Drug delivery devices and methods for treatment of viral and microbial infections and wasting syndromes
Eron Jr The treatment of antiretroviral-naive subjects with the 3TC/zidovudine combination: a review of North American (NUCA 3001) and European (NUCB 3001) trials
Martin et al. Effects of U-75875, a peptidomimetic inhibitor of retroviral proteases, on simian immunodeficiency virus infection in rhesus monkeys
Richman Antiviral therapy of HIV infection
Valentine et al. Phase I study of 2′, 3′-dideoxyinosine: experience with 19 patients at New York University Medical Center
LT4714B (lt) Vaistų įvedimo įtaisas ir farmacinė kompozicija, skirti gydyti sekinančius sindromus
Seifert et al. Pharmacokinetics of co‐administered didanosine and stavudine in HIV‐seropositive male patients.
Franssen et al. Didanosine, a new antiretroviral drug: A review
Mathes et al. Evidence that high-dosage zidovudine at time of retrovirus exposure reduces antiviral efficacy
Weber et al. Low-dose zidovudine in combination with either acyclovir or lymphoblastoid interferon-alpha in asymptomatic HIV-infected patients: a pilot study
WO1999060988A9 (en) Combination therapy for treatment of fiv infection
Fletcher et al. Advances in pharmacotherapy: treatment of HIV infection
Stellbrink et al. Antiviral and immunological effects of escalating low doses of zidovudine in HIV-positive patients
Mukherji Delivery and pharmacodynamics of dideoxynucleosides
Wang Evaluation of 5-halo-6-alkoxy (or azido)-5, 6-dihydro analogs as prodrugs of nucleoside reverse transcriptase inhibitors
Zhang et al. Pharmacokinetics of lamivudine in cats

Legal Events

Date Code Title Description
PC9A Transfer of patents

Free format text: 20010510 * VIRODENE PHARMACEUTICAL HOLDINGS (PTY),ZA

MM9A Lapsed patents

Effective date: 20020609